Asarina Pharma AB (publ)

Asarina Pharma AB (publ) — Shareholder Meeting (April 2021)

16 slides from Asarina Pharma AB (publ)'s shareholder meeting presentation, Apr 21, 2021

  1. Slide 1: Asarina Pharma Annual General Meeting

    ASARINA PHARMA Remain in control of your life Annual General Meeting 21 April 2021 Peter Nordkild, CEO 1

  2. Slide 2: Disclaimer

    Disclaimer • The shares of Asarina Pharma (”Asarina”) are traded on NASDAQ First North (ASAP) • This presentation may contain specific forward-looking statements, relating to Asarina´s future business, development and economic performance e.g. statements including terms like ”believe”, ”assume”, ”ex

  3. Slide 3: Introduction

    Introduction • Due to Covid-19 restrictions, Asarina management is unable to physically attend the Annual General Meeting • The following slides include the presentation by Peter Nordkild of the current situation in Asarina CONFIDENTIAL 3

  4. Slide 4: Highlights April 2021

    Highlights April 2021  Menstrual Migraine - 164 women enrolled; 86 women randomized in phase IIa study - On track to publish topline results in June 2021  Tourette Syndrome - 4 months tox study in juvenile animals completed without adverse events - Additional strong preclinical data in autopsy bas

  5. Slide 5: Sepranolone in Menstrual Migraine

    Sepranolone in Menstrual Migraine  1 out of 5 women migraineurs suffer from menstrual migraine (MM)  MM starts from 2 days before to 3 days into menstruation  MM pain does not respond well to current migraine therapeutics, especially not to prophylactic treatment  Sepranolone aims to prevent the

  6. Slide 6: Migraine Attacks During the Menstrual Cycle

    Migraine Attacks During the Menstrual Cycle Menstrual exacerbation of migraine occurs in ~ 50% of women with migraine MacGregor et al., NEUROLOGY 2006;67:2154–2158 Incidence of migraine, urinary estrone-3-glucuronide (E1G) and pregnanediol-3-glucuronide (PdG) levels on each day of the menstrual cycl

  7. Slide 7: Phase IIa Study – key design

    Phase IIa Study – key design • A randomized, double blind, parallel group study in women age 18-45 comparing two doses of Sepranolone and placebo. • A diagnostic/baseline phase of three menstrual cycles followed by three cycles of Sepranolone treatment. • Women self-administer Sepranolone every 48 h

  8. Slide 8: MM – market opportunity

    MM – market opportunity Market assumptions • Assumptions: > 6% of women suffer from Menstrual Migraine (~14.000.000) > 50% or 7 mio in EU/US/Japan seek treatment > 30% are refractory to present treatment Potential MM market for Sepranolone - Year of launch: 2028 - Penetration: 10% at peak sales = 2

  9. Slide 9: Tourette Syndrome

    Tourette Syndrome 2018 survey among TS children - 63% felt discriminated against - 32% have considered suicide - 40% were forced to miss school - 59% take prescription medications - 29% have tried 5 or more different medications Source: The US Tourette association Remain in control of your life 9 9

  10. Slide 10: Finasteride reduces tics and tic severity

    Finasteride, a 5α-reductase inhibitor that blocks ALLO production, reduces tics and tic severity Effects of finasteride (FIN) on severity of tics in patients with Tourette syndrome (n=16) FIN induced significant reductions in the severity of: (A) global symptoms (P<0.001) (B) total tics (P<0.001) (C

  11. Slide 11: High Sepranolone efficacy on par with Haldol and experimental Finasteride

    High Sepranolone efficacy on par with Haldol and experimental Finasteride Spatial confinement experiment in D1CT-7 transgenic mice 1.50 Vehicle (SC) P<0.0001 P<0.00001 1.25 Sepranolone (10 mg/kg, SC) P<0.00001 # Tics/min P<0.00001 Haloperidol (0.3 mg/kg, IP) 1.00 NS Finasteride (25 mg/kg, IP) 0.75 N

  12. Slide 12: Phase IIa study in TS - to be initiated in June 2021

    Phase IIa study in TS - to be initiated in June 2021 3mths Sepranolone 1 month + present treatment 30-60d screening 1 month baseline follow-up Present treatment • A randomized parallel group Phase IIa study in adolescents and adult patients with TS • ~30 male and female TS patients, age 12-45, rando

  13. Slide 13: Tourette Syndrome - Market Opportunity

    Tourette Syndrome - Market Opportunity Assumptions - 400.000 diagnosed TS patients in US/EU/Japan > 200.000 patients in US/EU/Japan treated with drugs - pediatric orphan drug designation requested with FDA Potential market for Sepranolone - Launch: 2028 - Market penetration: 20 % at peak sales = 40.

  14. Slide 14: Near term value inflection points

    Near term value inflection points 2021 2022 CTA APH205 study CTA Phase APH205 study in initiation in IIb study Initiation Phase Tourette Tourette in MM IIb trial MM Menstrual Top line Migraine results last patient Menstrual Tourette Top last dose Migraine Line data March `21 March `21 June `21 June

  15. Slide 15: Financial highlights

    Financial highlights  Operating costs adjusted after PMDD data, incl. reduction in headcount – senior team intact Total operating costs at same level as 2019  SEK 7 million received in tax credit Cash available at year-end: SEK 58.5 million – will cover both phase IIa studies 1Thelanasis Tourett

  16. Slide 16: Thank you, questions?

    » ASARINA PHARMA THANK YOU QUESTIONS?

Asarina Pharma — Shareholder Meeting (April 2021) on 6ix